Nociceptin

Nociceptin (Orphanin FQ) is a 17-amino acid neuropeptide and the endogenous ligand for the NOP receptor (ORL-1, opioid receptor-like 1). Structurally related to the opioid peptide dynorphin, nociceptin activates an opioid-like receptor but does not bind classical mu, kappa, or delta opioid receptors. It produces complex, site-dependent effects on pain modulation and is studied as a non-addictive analgesic target due to the absence of classical opioid reward signaling.

Nociceptin binds selectively and with high affinity to the NOP receptor, activating Gi/Go proteins to inhibit adenylyl cyclase, decrease cAMP, suppress voltage-gated calcium channels, and activate inwardly rectifying potassium channels. These actions reduce neuronal excitability. Supraspinally, NOP activation counteracts opioid analgesia and morphine-induced reward, while spinally and peripherally it produces analgesic effects. The absence of NOP receptor coupling to the mesolimbic dopamine reward pathway distinguishes nociceptin from classical opioids, supporting its non-addictive profile.

NOP receptor research has identified nociceptin as a modulator of pain, anxiety, stress, reward, and memory. Selective NOP receptor ligands are in clinical development: cebranopadol (mixed NOP/opioid agonist) has shown efficacy in phase II/III trials for chronic low back pain. Sunobinop (partial NOP agonist) promotes non-REM sleep in rodents and early human trials. The NOP system's ability to reduce opioid tolerance and reward makes it a target for opioid use disorder research. Nociceptin also modulates immune function and cardiovascular tone.